AMLX Latest Press Releases

-- November 14, 2026 --

Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek 2026 Annual Meeting Business Wire 12:00 PM

-- November 5, 2026 --

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results Business Wire 7:00 AM

-- November 4, 2026 --

Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek 2026 Featuring Leading PBH Experts Business Wire 9:00 AM

-- November 3, 2026 --

Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences Business Wire 9:00 AM

-- November 2, 2026 --

Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 Business Wire 9:00 AM

-- October 6, 2026 --

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek 2026 Annual Meeting Business Wire 8:00 AM

-- September 23, 2026 --

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum Business Wire 9:00 AM

-- September 9, 2026 --

Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors Business Wire 8:00 AM

-- September 8, 2026 --

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference Business Wire 9:00 AM

-- August 19, 2026 --

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock Business Wire 11:06 PM

-- August 18, 2026 --

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock Business Wire 4:01 PM

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia Business Wire 7:00 AM

-- August 17, 2026 --

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 Business Wire 4:01 PM

-- August 6, 2026 --

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results Business Wire 7:00 AM

-- August 3, 2026 --

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 Business Wire 9:00 AM

-- July 3, 2026 --

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PRNewswire 12:15 PM

-- June 23, 2026 --

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 Business Wire 7:00 AM

Market Data Delayed 15 Minutes